Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone vs Spironolactone in Primary Aldosteronism
NCT07688928Recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial of finerenone in primary aldosteronism (PA) and hypertension (HTN) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoints: Dose of Finerenone required to attain composite endpoint at 12 months and Time required to attain composite endpoint at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
finerenone
03
Conditions
primary aldosteronism (PA)hypertension (HTN)
Beyond the preview
Go deeper on NCT07688928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688928.